About the Company
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EYEN News
Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 18, 2024 Eyenovia, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of ...
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago. These figures are ...
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare ...
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its financial and operating results for the fourth quarter and ...
US FDA approves Eyenovia's eye drug, Formosa Pharma says
The U.S. Food and Drug Administration approved Eyenovia's eye drops to reduce inflammation and pain in patients who have undergone eye surgery, Formosa Pharmaceuticals said on Monday.
Eyenovia’s Strategic Commercial Synergy and Growth Potential Reinforce Buy Rating
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Eyenovia (EYEN – Research Report), with a ...
Earnings Preview For Eyenovia
Analysts estimate that Eyenovia will report an earnings per share (EPS) of $-0.17. Eyenovia bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide ...
Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their ...
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology ...
Stocks Settle Lower as Bond Yields Climb on Inflation Concerns
Costar Group ( CSGP) closed up more than +8% to lead gainers in the S&P 500 and the Nasdaq 100 after the National Association of Realtors agreed to a $418 million deal to settle litigation over ...
Stocks Rally on Strength in Technology Stocks
The S&P 500 Index ( $SPX) ( SPY) this morning is up +1.00%, the Dow Jones Industrials Index ( $DOWI ) ( DIA) is up +0.24%, and the Nasdaq 100 Index ( $IUXX) ( QQQ) is up +1.67%.
Q4 2023 Eyenovia Inc Earnings Call
Matthew Caufield; Analyst; H.C. Wainwright & Co., LLC ...
Loading the latest forecasts...